Dual-action cancer therapy with targeted porous silicon nanovectors

Anna Cifuentes Rius, Angela Ivask, Ester Sporleder, Ishdeep Kaur, Yasmin Assan, Shasha Rao, David Warther, Clive A Prestidge, Jean-Olivier Durand, Nicolas Voelcker

Research output: Contribution to journalArticleResearchpeer-review

Abstract

There is a pressing need to develop more effective therapeutics to fight cancer. An idyllic chemotherapeutic is expected to overcome drug resistance of tumors and minimize harmful side effects to healthy tissues. Antibody-functionalized porous silicon nanoparticles loaded with a combination of chemotherapy drug and gold nanoclusters (AuNCs) are developed. These nanocarriers are observed to selectively deliver both payloads, the chemotherapy drug and AuNCs, to human B cells. The accumulation of AuNCs to target cells and subsequent exposure to an external electromagnetic field in the microwave region render them more susceptible to the codelivered drug. This approach represents a targeted two-stage delivery nanocarrier that benefits from a dual therapeutic action that results in enhanced cytotoxicity.

Original languageEnglish
Number of pages6
JournalSmall
DOIs
Publication statusAccepted/In press - 2017

Keywords

  • Cancer
  • Cytotoxicity
  • Drug delivery
  • Nanoparticles

Cite this

Cifuentes Rius, Anna ; Ivask, Angela ; Sporleder, Ester ; Kaur, Ishdeep ; Assan, Yasmin ; Rao, Shasha ; Warther, David ; Prestidge, Clive A ; Durand, Jean-Olivier ; Voelcker, Nicolas. / Dual-action cancer therapy with targeted porous silicon nanovectors. In: Small. 2017.
@article{2963166ae1604e518c34e5af47356714,
title = "Dual-action cancer therapy with targeted porous silicon nanovectors",
abstract = "There is a pressing need to develop more effective therapeutics to fight cancer. An idyllic chemotherapeutic is expected to overcome drug resistance of tumors and minimize harmful side effects to healthy tissues. Antibody-functionalized porous silicon nanoparticles loaded with a combination of chemotherapy drug and gold nanoclusters (AuNCs) are developed. These nanocarriers are observed to selectively deliver both payloads, the chemotherapy drug and AuNCs, to human B cells. The accumulation of AuNCs to target cells and subsequent exposure to an external electromagnetic field in the microwave region render them more susceptible to the codelivered drug. This approach represents a targeted two-stage delivery nanocarrier that benefits from a dual therapeutic action that results in enhanced cytotoxicity.",
keywords = "Cancer, Cytotoxicity, Drug delivery, Nanoparticles",
author = "{Cifuentes Rius}, Anna and Angela Ivask and Ester Sporleder and Ishdeep Kaur and Yasmin Assan and Shasha Rao and David Warther and Prestidge, {Clive A} and Jean-Olivier Durand and Nicolas Voelcker",
year = "2017",
doi = "10.1002/smll.201701201",
language = "English",
journal = "Small",
issn = "1613-6810",
publisher = "Wiley-Blackwell",

}

Cifuentes Rius, A, Ivask, A, Sporleder, E, Kaur, I, Assan, Y, Rao, S, Warther, D, Prestidge, CA, Durand, J-O & Voelcker, N 2017, 'Dual-action cancer therapy with targeted porous silicon nanovectors' Small. https://doi.org/10.1002/smll.201701201

Dual-action cancer therapy with targeted porous silicon nanovectors. / Cifuentes Rius, Anna; Ivask, Angela; Sporleder, Ester; Kaur, Ishdeep; Assan, Yasmin; Rao, Shasha; Warther, David; Prestidge, Clive A; Durand, Jean-Olivier; Voelcker, Nicolas.

In: Small, 2017.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Dual-action cancer therapy with targeted porous silicon nanovectors

AU - Cifuentes Rius, Anna

AU - Ivask, Angela

AU - Sporleder, Ester

AU - Kaur, Ishdeep

AU - Assan, Yasmin

AU - Rao, Shasha

AU - Warther, David

AU - Prestidge, Clive A

AU - Durand, Jean-Olivier

AU - Voelcker, Nicolas

PY - 2017

Y1 - 2017

N2 - There is a pressing need to develop more effective therapeutics to fight cancer. An idyllic chemotherapeutic is expected to overcome drug resistance of tumors and minimize harmful side effects to healthy tissues. Antibody-functionalized porous silicon nanoparticles loaded with a combination of chemotherapy drug and gold nanoclusters (AuNCs) are developed. These nanocarriers are observed to selectively deliver both payloads, the chemotherapy drug and AuNCs, to human B cells. The accumulation of AuNCs to target cells and subsequent exposure to an external electromagnetic field in the microwave region render them more susceptible to the codelivered drug. This approach represents a targeted two-stage delivery nanocarrier that benefits from a dual therapeutic action that results in enhanced cytotoxicity.

AB - There is a pressing need to develop more effective therapeutics to fight cancer. An idyllic chemotherapeutic is expected to overcome drug resistance of tumors and minimize harmful side effects to healthy tissues. Antibody-functionalized porous silicon nanoparticles loaded with a combination of chemotherapy drug and gold nanoclusters (AuNCs) are developed. These nanocarriers are observed to selectively deliver both payloads, the chemotherapy drug and AuNCs, to human B cells. The accumulation of AuNCs to target cells and subsequent exposure to an external electromagnetic field in the microwave region render them more susceptible to the codelivered drug. This approach represents a targeted two-stage delivery nanocarrier that benefits from a dual therapeutic action that results in enhanced cytotoxicity.

KW - Cancer

KW - Cytotoxicity

KW - Drug delivery

KW - Nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=85020129752&partnerID=8YFLogxK

U2 - 10.1002/smll.201701201

DO - 10.1002/smll.201701201

M3 - Article

JO - Small

JF - Small

SN - 1613-6810

ER -